Abstract
The vaptans constitute a new class of pharmaceuticals developed for the treatment of the hypervolemic and euvolemic forms of hyponatremia. These agents are nonpeptide vasopressin antagonists that interfere with the antidiuretic effect of the hormone by competitively binding to V2 receptors in the kidney. This blockade results in water diuresis (aquaresis) that, if not offset by increased fluid intake, reduces body water content and raises plasma sodium levels. Probably as a result of this rise in plasma sodium, thirst and plasma vasopressin concentration increase, potentionally limiting the effects of the vasopressin antagonists. Nonetheless, vaptans are particularly useful to treat hypervolemic hyponatremia associated with severe congestive heart failure or chronic liver failure, as the only other treatments currently available, such as fluid restriction and diuretics, are slow-acting and minimally effective. Vaptans are also useful for treating euvolemic hyponatremia associated with the syndrome of inappropriate antidiuretic hormone (SIADH), at least when it is chronic and/or minimally symptomatic. However, because their effects vary unpredictably from patient to patient, vaptans are less useful than hypertonic saline infusion in cases of acute, severe and symptomatic hyponatremia. Vaptan therapy is absolutely contraindicated in hypovolemic hyponatremia (in which total body water is reduced) and is ineffective in the vasopressin-independent form of inappropriate antidiuresis caused by constitutive activating mutations of V2 receptors.
Key Points
-
Vaptans are nonpeptide agents that antagonize the antidiuretic effect of vasopressin by competing with it for binding to V2 receptors in the kidney
-
Vaptans increase solute-free water excretion, reduce body water content and raise the plasma sodium level by reducing urine concentration, unless the aquaresis is offset by increased fluid intake
-
The vaptan-induced rise in plasma sodium often stimulates thirst and/or vasopressin secretion, which, in turn, may feed back to increase fluid intake and/or overcome blockade of the V2 receptor
-
In conjunction with modest restriction of fluid intake, vaptans have proven safe and effective in treating chronic hypervolemic and euvolemic hyponatremia
-
The use of vaptans to treat acute, symptomatic forms of hyponatremia is still debatable, because their effects on plasma sodium vary unpredictably from patient to patient
-
Vaptan therapy is contraindicated in hypovolemic hyponatremia, a disorder associated with decreased total body water and sodium levels, and is ineffective in a form of inappropriate antidiuresis that is independent of vasopressin
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Robertson, G. L., Aycinena, P. & Zerbe, R. L. Neurogenic disorders of osmoregulation. Am. J. Med. 72, 339–353 (1982).
Robertson, G. L. Regulation of arginine vasopressin in the syndrome of inappropriate antidiuresis. Am. J. Med. 119 (Suppl. 1), S36–S42 (2006).
Schrier, R. W. Water and sodium retention in edematous disorders: role of vasopressin and aldosterone. Am. J. Med. 119 (Suppl. 1), S47–S53 (2006).
Pruszczynski, W., Vahanian, A., Ardaillou, R. & Acar, J. Role of antidiuretic hormone in impaired water excretion of patients with congestive heart failure. J. Clin. Endocrinol. Metab. 58, 599–605 (1984).
Robertson, G. L. The use of vasopressin assays in physiology and pathophysiology. Semin. Nephrol. 14, 368–383 (1994).
Oelkers, W. Hyponatremia and inappropriate secretion of vasopressin (antidiuretic hormone) in patients with hypopituitarism. N. Engl. J. Med. 321, 492–496 (1989).
Gitelman, S. E., Feldman, B. J. & Rosenthal, S. M. Nephrogenic syndrome of inappropriate antidiuresis: a novel disorder in water balance in pediatric patients. Am. J. Med. 119 (Suppl. 1), S54–S58 (2006).
Decaux, G. et al. Nephrogenic syndrome of inappropriate antidiuresis in adults: high phenotypic variability in men and women from a large pedigree. J. Am. Soc. Nephrol. 18, 606–612 (2007).
Robertson, G. L. Antidiuretic hormone. Normal and disordered function. Endocrinol. Metab. Clin. North Am. 30, 671–694 (2001).
Pasantes-Morales, H., Lezama, R. A., Ramos-Mandujano, G. & Tuz, K. L. Mechanisms of cell volume regulation in hypo-osmolality. Am. J. Med. 119 (Suppl. 1), S4–S11 (2006).
Sterns, R. H. & Silver, S. M. Brain volume regulation in response to hypo-osmolality and its correction. Am. J. Med. 119 (Suppl. 1), S12–S16 (2006).
Shimizu, K. Aquaretic effects of the nonpeptide V2 antagonist OPC-31260 in hydropenic humans. Kidney Int. 48, 220–226 (1995).
Ohnishi, A. et al. Potent aquaretic agent. A novel nonpeptide selective vasopressin 2 antagonist (OPC-31260) in men. J. Clin. Invest. 92, 2653–2659 (1993).
Ohnishi, A. et al. Aquaretic effect of a potent, orally active, non-peptide V2 antagonist in men. J. Pharmacol. Exp. Ther. 272, 546–551 (1995).
Burnier, M., Fricker, A. F., Hayoz, D., Nussberger, J. & Brunner, H. R. Pharmacokinetic and pharmacodynamic effects of YM087, a combined V1/V2 vasopressin receptor antagonist in normal subjects. Eur. J. Clin. Pharmacol. 55, 633–637 (1999).
Mao, Z. L., Stalker, D. & Keirns, J. Pharmacokinetics of conivaptan hydrochloride, a Vasopressin V1a/V2-receptor antagonist, in patients with euvolemic or hypervolemic hyponatremia and with or without congestive heart failure from a prospective, 4-day open-label study. Clin. Ther. 31, 1542–1550 (2009).
Matsuhisa, A., Taniguchi, N., Koshio, H., Yatsu, T. & Tanaka, A. Nonpeptide arginine vasopressin antagonists for both V1A and V2 receptors: synthesis and pharmacological properties of 4-(1,4,5,6-tetrahydroimidazo[4,5-d][1]benzoazepine-6-carbonyl)benzanili de derivatives and 4′-(5,6-dihydro-4H-thiazolo[5,4-d][1]benzoazepine-6-carbonyl)benzanilid e derivatives. Chem. Pharm. Bull. (Tokyo) 48, 21–31 (2000).
Shoaf, S. E., Wang, Z., Bricmont, P. & Mallikaarjun, S. Pharmacokinetics, pharmacodynamics, and safety of tolvaptan, a nonpeptide AVP antagonist, during ascending single-dose studies in healthy subjects. J. Clin. Pharmacol. 47, 1498–1507 (2007).
Serradeil-Le Gal, C. An overview of SR121463, a selective, non-peptide vasopressin V(2) receptor antagonist. Cardiovasc. Drug Rev. 19, 201–214 (2001).
Albright, J. D. et al. 5-Fluoro-2-methyl-N-[4-(5H-pyrrolo[2,1-c]-[1, 4]benzodiazepin-10(11H)-ylcarbonyl)-3-chlorophenyl]benzamide (VPA-985): an orally active arginine vasopressin antagonist with selectivity for V2 receptors. J. Med. Chem. 41, 2442–2444 (1998).
Martinez-Castelao, A. Lixivaptan (American Home Products). Curr. Opin. Investig. Drugs 2, 525–530 (2001).
Muralidharan, G. et al. Pharmacokinetics and pharmacodynamics of a novel vasopressin receptor antagonist, VPA-985, in healthy subjects. Clin. Pharmacol. Ther. 65, 189 (1999).
Guyader, D., Patat, A., Ellis-Grosse, E. J. & Orczyk, G. P. Pharmacodynamic effects of a nonpeptide antidiuretic hormone V2 antagonist in cirrhotic patients with ascites. Hepatology 36, 1197–1205 (2002).
Gunnet, J. W. et al. Characterization of RWJ-351647, a novel non-peptide vasopressin V2 receptor antagonist. Clin. Exper. Pharmacol. Physiol. 33, 320–326 (2006).
Robertson, G. L., Shelton, R. L. & Athar, S. The osmoregulation of vasopressin. Kidney Int. 10, 25–37 (1976).
Zerbe, R. L., Miller, J. Z. & Robertson, G. L. The reproducibility and heritability of individual differences in osmoregulatory function in normal human subjects. J. Lab. Clin. Med. 117, 51–59 (1991).
Ghali, J. K. et al. Efficacy and safety of oral conivaptan: a V1A/V2 vasopressin receptor antagonist, assessed in a randomized, placebo-controlled trial in patients with euvolemic or hypervolemic hyponatremia. J. Clin. Endocrinol. Metab. 91, 2145–2152 (2006).
Annane, D., Decaux, G. & Smith, N. Efficacy and safety of oral conivaptan, a vasopressin-receptor antagonist, evaluated in a randomized, controlled trial in patients with euvolemic or hypervolemic hyponatremia. Am. J. Med. Sci. 337, 28–36 (2009).
Zeltser, D., Rosansky, S., van Rensburg, H., Verbalis, J. G. & Smith, N. Assessment of the efficacy and safety of intravenous conivaptan in euvolemic and hypervolemic hyponatremia. Am. J. Nephrol. 27, 447–457 (2007).
Schrier, R. W. et al. Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia. N. Engl. J. Med. 355, 2099–2112 (2006).
Gheorghiade, M. et al. Vasopressin v(2) receptor blockade with tolvaptan versus fluid restriction in the treatment of hyponatremia. Am. J. Cardiol. 97, 1064–1067 (2006).
Wong, F., Blei, A. T., Blendis, L. M. & Thuluvath, P. J. A vasopressin receptor antagonist (VPA-985) improves serum sodium concentration in patients with hyponatremia: a multicenter, randomized, placebo-controlled trial. Hepatology 37, 182–191 (2003).
Gheorghiade, M. et al. Vasopressin V2-receptor blockade with tolvaptan in patients with chronic heart failure: results from a double-blind, randomized trial. Circulation 107, 2690–2696 (2003).
Abraham, W. T., Shamshirsaz, A. A., McFann, K., Oren, R. M. & Schrier, R. W. Aquaretic effect of lixivaptan, an oral, non-peptide, selective V2 receptor vasopressin antagonist, in New York Heart Association functional class II and III chronic heart failure patients. J. Am. Coll. Cardiol. 47, 1615–1621 (2006).
Rossi, J. et al. Improvement in hyponatremia during hospitalization for worsening heart failure is associated with improved outcomes: insights from the Acute and Chronic Therapeutic Impact of a Vasopressin Antagonist in Chronic Heart Failure (ACTIV in CHF) trial. Acute Card. Care 9, 82–86 (2007).
Konstam, M. A. et al. Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial. JAMA 297, 1319–1331 (2007).
Inoue, T. et al. Therapeutic and diagnostic potential of a vasopressin-2 antagonist for impaired water handling in cirrhosis. Clin. Pharmacol. Ther. 63, 561–570 (1998).
Ginès, P. et al. Effects of satavaptan, a selective vasopressin V(2) receptor antagonist, on ascites and serum sodium in cirrhosis with hyponatremia: a randomized trial. Hepatology 48, 204–213 (2008).
Verbalis, J. G., Zeltser, D., Smith, N., Barve, A. & Andoh, M. Assessment of the efficacy and safety of intravenous conivaptan in patients with euvolaemic hyponatraemia: subgroup analysis of a randomized, controlled study. Clin. Endocrinol. (Oxf.) 69, 159–168 (2008).
O'Leary, J. G. & Davis, G. L. Conivaptan increases serum sodium in hyponatremic patients with end-stage liver disease. Liver Transpl. 15, 1325–1329 (2009).
Soupart, A. et al. Successful long-term treatment of hyponatremia in syndrome of inappropriate antidiuretic hormone secretion with satavaptan (SR121463B), an orally active nonpeptide vasopressin V2-receptor antagonist. Clin. J. Am. Soc. Nephrol. 1, 1154–1160 (2006).
Goldman, M. B., Luchins, D. J. & Robertson, G. L. Mechanisms of altered water metabolism in psychotic patients with polydipsia and hyponatremia. N. Engl. J. Med. 318, 397–403 (1988).
Josiassen, R. C. et al. Double-blind, placebo-controlled, multicenter trial of a vasopressin V2-receptor antagonist in patients with schizophrenia and hyponatremia. Biol. Psychiatry 64, 1097–1100 (2008).
Decaux, G. et al. Nephrogenic syndrome of inappropriate antidiuresis in adults: high phenotypic variability in men and women from a large pedigree. J. Am. Soc. Nephrol. 18, 606–612 (2007).
Berliner, R. W., Levinsky, N. G., Davidson, D. G. & Eden, M. Dilution and concentration of the urine and the action of the antidiuretic hormone. Am. J. Med. 24, 730–744 (1958).
Knepper, M. A. Molecular physiology of urinary concentrating mechanism: regulation of aquaporin water channels by vasopressin. Am. J. Physiol. 272, F3–F12 (1997).
Acknowledgements
C. P. Vega, University of California, Irvine, CA, is the author of and is solely responsible for the content of the learning objectives, questions and answers of the MedscapeCME-accredited continuing medical education activity associated with this article.
Author information
Authors and Affiliations
Ethics declarations
Competing interests
The author declares no competing financial interests.
Rights and permissions
About this article
Cite this article
Robertson, G. Vaptans for the treatment of hyponatremia. Nat Rev Endocrinol 7, 151–161 (2011). https://doi.org/10.1038/nrendo.2010.229
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrendo.2010.229
This article is cited by
-
Endocrine system dysfunction and chronic heart failure: a clinical perspective
Endocrine (2022)
-
Effect of tolvaptan on renal water and sodium excretion and blood pressure during nitric oxide inhibition: a dose-response study in healthy subjects
BMC Nephrology (2017)
-
Copeptin in the diagnosis of vasopressin-dependent disorders of fluid homeostasis
Nature Reviews Endocrinology (2016)
-
Hyponatremia in the intensive care unit: How to avoid a Zugzwang situation?
Annals of Intensive Care (2015)
-
Effect of vasopressin antagonism on renal handling of sodium and water and central and brachial blood pressure during inhibition of the nitric oxide system in healthy subjects
BMC Nephrology (2014)